Maze Therapeutics, Inc.
MAZE
$7.83
$0.233.03%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | ||
|---|---|---|---|---|---|
| Net Income | -11.30% | -0.02% | 317.07% | 317.07% | |
| Total Depreciation and Amortization | -27.77% | -21.51% | -14.46% | -14.46% | |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | |
| Total Other Non-Cash Items | -25.19% | 113.35% | 82.16% | 82.16% | |
| Change in Net Operating Assets | 145.86% | -643.30% | 153.23% | 153.23% | |
| Cash from Operations | -8.76% | -16.19% | 363.16% | 363.16% | |
| Capital Expenditure | -1,679.41% | -3,533.33% | -7.07% | -7.07% | |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | |
| Cash Acquisitions | -- | -- | -- | -- | |
| Divestitures | -- | -- | -- | -- | |
| Other Investing Activities | -- | -- | -- | -- | |
| Cash from Investing | -1,679.41% | -3,533.33% | -7.07% | -7.07% | |
| Total Debt Issued | -100.00% | -- | -- | -- | |
| Total Debt Repaid | -- | -- | -- | -- | |
| Issuance of Common Stock | 425.00% | 2,725.00% | 134.92% | 134.92% | |
| Repurchase of Common Stock | -- | -- | -- | -- | |
| Issuance of Preferred Stock | -- | -- | -- | -- | |
| Repurchase of Preferred Stock | -- | -- | -- | -- | |
| Total Dividends Paid | -- | -- | -- | -- | |
| Other Financing Activities | -- | -- | -- | -- | |
| Cash from Financing | 334.04% | -26,975.00% | 12,987.30% | 12,987.30% | |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | |
| Net Change in Cash | 1,151.57% | -27.54% | 414.23% | 414.23% | |